Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.3863 USD -0.15 ( 28.54%)
Last update at 2026-11-06T21:01:00Z
VOLUME
30465851
Market Cap
5.14M

Momentum Score

…

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.33
Low
0.49
High
52 Week Price Range
0.58
Low
9.82
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) is a development-stage biotherapeutics company; public disclosures about its pipeline and operations are limited. Long-term growth may depend on clinical development milestones, regulatory approvals, strategic partnerships and successful financing, which could support value creation for investors.
Primary risks include clinical and regulatory failure, ongoing funding requirements leading to dilution, limited operating history and low liquidity for the stock.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.54
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.85
ROE
-402.84%
Net Debt
1.42M
ROCE
194.79%
Diluted EPS TTM
-3.23

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Income before tax -3.85M -4.86M -8.28M
Net income -3.85M -4.86M -8.28M
Selling general administrative 2.51M 1.92M 3.10M
Reconciled depreciation 0.12M 0.12M 0.12M
Ebit -3.75M -4.85M -8.27M
Ebitda -3.63M -4.73M -8.15M
Depreciation and amortization 0.12M 0.12M 0.12M
Operating income -3.77M -4.03M -8.64M
Other operating expenses 3.77M 4.03M 8.64M
Interest expense 0.10M 0.01M 0.01M
Interest income 0.03M 0.14M 0.36M
Net interest income -0.08M 0.14M 0.35M
Total revenue 0.00M 0.00M 0.00M
Total operating expenses 3.77M 4.03M 8.64M
Total other income expense net -0.08M -0.83M 0.35M
Net income from continuing ops -3.85M -4.86M -8.28M
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Total assets 0.48M 1.07M 6.89M
Other current assets 0.07M 0.09M 0.09M
Total liab 2.45M 0.66M 2.34M
Total stockholder equity -1.96M 0.41M 4.56M
Other current liab 0.40M - -
Common stock 0.00M - -
Capital stock 0.00M 0.00M 0.00M
Retained earnings -53.35M -49.50M -44.65M
Cash 0.24M 0.68M 2.53M
Total current liabilities 2.41M 0.50M 2.06M
Net debt 1.42M - -
Short term debt 1.62M - -
Short long term debt 1.50M - 0.20M
Short long term debt total 1.66M - -
Other stockholder equity 51.38M - -
Total current assets 0.31M 0.77M 6.48M
Short term investments - 0.00M 3.86M
Accounts payable 0.38M 0.17M 0.50M
Non currrent assets other 0.01M 0.01M 0.01M
Non current assets total 0.18M 0.30M 0.41M
Capital lease obligations 0.16M 0.27M 0.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Investments 0.00M 3.93M -3.78M
Net borrowings 1.50M 0.00M -
Total cash from financing activities 1.50M -0.05M 0.00M
Net income -3.85M -4.86M -8.28M
Change in cash -0.44M -1.85M -10.60M
Begin period cash flow 0.68M 2.53M 13.13M
End period cash flow 0.24M 0.68M 2.53M
Total cash from operating activities -1.94M -5.72M -6.82M
Depreciation 0.12M 0.12M 0.12M
Sale purchase of stock 0.00M -0.05M 0.00M
Capital expenditures 0.00M 0.00M 0.00M
Change in working capital 0.43M -1.19M 0.81M
Stock based compensation 1.35M 0.27M 0.61M
Free cash flow -1.94M -5.73M -6.82M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock		 -0.15
28.54%		 0.39 - - - 1.18
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

8031 Cooper Creek Blvd., University Park, FL, United States, 34201

941 225 2515

https://lakewoodamedex.com

5

Name Title Year Born
Dr. Kelvin Cooper Ph.D. CEO, SVP of Research & Development and Director 1956
Mr. Peter F. Ceccacci CFO & VP of Administration 1955
Dr. Thomas Balzer M.D., Ph.D. Chief Medical Officer & SVP of Clinical Development 1960
Ms. Tara Endress Project Manager & Accounting Manager NA
Daniel Kontoh-Boateng Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…